PDS BIOTECHNOLOGY CORP (PDSB) Stock Price, Quote, News and Overview
NASDAQ:PDSB - Nasdaq - US70465T1079 - Common Stock - Currency: USD
PDSB Quote, Performance and Key Statistics
1.27
+0.05 (+4.1%)
The current stock price of PDSB is 1.27 USD. In the past month the price decreased by -16.99%. In the past year, price decreased by -59.29%.
PDSB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.57 | 336.94B | ||
| AMGN | AMGEN INC | 14.3 | 159.62B | ||
| GILD | GILEAD SCIENCES INC | 14.41 | 138.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.00B | ||
| ARGX | ARGENX SE - ADR | 94.8 | 33.28B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.23 | 26.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.02B | ||
| NTRA | NATERA INC | N/A | 22.06B | ||
| BIIB | BIOGEN INC | 8.42 | 19.52B | ||
| INSM | INSMED INC | N/A | 17.89B |
Related stock screener links
About PDSB
Company Profile
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. The company is headquartered in Princeton, New Jersey and currently employs 24 full-time employees. The company went IPO on 2015-10-01. The firm is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Company Info
PDS BIOTECHNOLOGY CORP
303A College Road East
Princeton NEW JERSEY 07932 US
CEO: Frank Bedu-Addo
Employees: 24
Phone: 18002083343
PDS BIOTECHNOLOGY CORP / PDSB FAQ
What is the stock price of PDS BIOTECHNOLOGY CORP today?
The current stock price of PDSB is 1.27 USD. The price increased by 4.1% in the last trading session.
What is the ticker symbol for PDS BIOTECHNOLOGY CORP stock?
The exchange symbol of PDS BIOTECHNOLOGY CORP is PDSB and it is listed on the Nasdaq exchange.
On which exchange is PDSB stock listed?
PDSB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PDS BIOTECHNOLOGY CORP stock?
9 analysts have analysed PDSB and the average price target is 7.65 USD. This implies a price increase of 502.36% is expected in the next year compared to the current price of 1.27. Check the PDS BIOTECHNOLOGY CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PDS BIOTECHNOLOGY CORP worth?
PDS BIOTECHNOLOGY CORP (PDSB) has a market capitalization of 58.05M USD. This makes PDSB a Micro Cap stock.
How many employees does PDS BIOTECHNOLOGY CORP have?
PDS BIOTECHNOLOGY CORP (PDSB) currently has 24 employees.
What are the support and resistance levels for PDS BIOTECHNOLOGY CORP (PDSB) stock?
PDS BIOTECHNOLOGY CORP (PDSB) has a resistance level at 1.59. Check the full technical report for a detailed analysis of PDSB support and resistance levels.
Should I buy PDS BIOTECHNOLOGY CORP (PDSB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PDSB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PDSB, evaluating the profitability, health, valuation and growth aspects
- PDS BIOTECHNOLOGY CORP (PDSB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PDS BIOTECHNOLOGY CORP (PDSB) Sales and EPS estimates to see what analysts future expectations are.
- PDS BIOTECHNOLOGY CORP (PDSB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PDS BIOTECHNOLOGY CORP (PDSB) Insider and Institutional Ownership to learn about the owners and their transactions.
- PDS BIOTECHNOLOGY CORP (PDSB) Stock Chart to make your own analysis
- PDS BIOTECHNOLOGY CORP (PDSB) Latest news and press-releases to stay up to date.
Does PDS BIOTECHNOLOGY CORP (PDSB) stock pay dividends?
PDSB does not pay a dividend.
When does PDS BIOTECHNOLOGY CORP (PDSB) report earnings?
PDS BIOTECHNOLOGY CORP (PDSB) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of PDS BIOTECHNOLOGY CORP (PDSB)?
PDS BIOTECHNOLOGY CORP (PDSB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of PDS BIOTECHNOLOGY CORP (PDSB) stock?
The outstanding short interest for PDS BIOTECHNOLOGY CORP (PDSB) is 4.49% of its float. Check the ownership tab for more information on the PDSB short interest.
PDSB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to PDSB. When comparing the yearly performance of all stocks, PDSB is a bad performer in the overall market: 87.36% of all stocks are doing better.
PDSB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PDSB. PDSB may be in some trouble as it scores bad on both profitability and health.
PDSB Financial Highlights
Over the last trailing twelve months PDSB reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 31.39% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.48% | ||
| ROE | -158.73% | ||
| Debt/Equity | 0.29 |
PDSB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to PDSB. The Buy consensus is the average rating of analysts ratings from 9 analysts.